TCRX
TScan Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.10
P/S
5.73
EV/EBITDA
-0.01
DCF Value
$-4.23
FCF Yield
-236.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.6%
Operating Margin
-1315.4%
Net Margin
-1256.8%
ROE
-79.4%
ROA
-56.7%
ROIC
-62.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.6M | $-23.0M | $-0.18 |
| FY 2025 | $10.3M | $-129.8M | $-1.00 |
| Q3 2025 | $2.5M | $-35.7M | $-0.28 |
| Q2 2025 | $3.1M | $-37.0M | $-0.28 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.01
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.